Biogen Inc

$ 224.4 0 (0%)
Volume: 4,115,130 Avg Vol (1m): 2,318,764
Market Cap $: 44.14 Bil Enterprise Value $: 46.53 Bil
P/E (TTM): 10.39 P/B: 3.39
Earnings Power Value 173.4
Net Current Asset Value -23.37
Tangible Book 21.37
Projected FCF 253.15
Median P/S Value 341.27
Graham Number 101.9
Peter Lynch Value 405
DCF (FCF Based) 277.54
DCF (Earnings Based) 614.92
YTD (-%)

Financial Strength : 7/10

Current vs industry vs history
Cash-to-Debt 0.60
Equity-to-Asset 0.52
Debt-to-Equity 0.46
Debt-to-EBITDA 0.83
Interest Coverage 29.35
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.65
DISTRESS
GREY
SAFE
Beneish M-Score -2.70
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 29.95%
WACC 12.34%

Profitability & Growth : 9/10

Current vs industry vs history
Operating Margin % 43.77
Net Margin % 32.93
ROE % 33.70
ROA % 17.80
ROC (Joel Greenblatt) % 138.67
3-Year Total Revenue Growth Rate 7.70
3-Year Total EBITDA Growth Rate 9.20
3-Year EPS w/o NRI Growth Rate 12.00

» BIIB's 30-Y Financials

Financials (Next Earnings Date: 2019-04-24)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BIIB

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare ASX:CSL LSE:SHP NAS:CELG NAS:VRTX NAS:REGN XKRX:068270 XKRX:207940 NAS:ALXN NAS:GILD HKSE:01177 XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV HKSE:02269 NAS:JUNO
Traded in other countries BIIB34.Brazil IDP.Germany 0R1B.UK
Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen markets novel MS drugs Tysabri and Tecfidera independently. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Ratios

Current vs industry vs history
PE Ratio (TTM) 10.39
Forward PE Ratio 8.00
N/A
PE Ratio without NRI 10.39
Price-to-Owner-Earnings 8.73
PB Ratio 3.39
PS Ratio 3.42
Price-to-Free-Cash-Flow 8.67
Price-to-Operating-Cash-Flow 7.42
EV-to-EBIT 7.64
EV-to-EBITDA 6.54
EV-to-Revenue 3.46
PEG Ratio 0.53
Shiller PE Ratio 20.48
Current Ratio 2.32
Quick Ratio 2.04
Days Inventory 183.74
Days Sales Outstanding 67.43
Days Payable 74.45

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 3.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.50
Price-to-Projected-FCF 0.89
Price-to-DCF (Earnings Based) 0.36
Price-to-Median-PS-Value 0.66
Price-to-Peter-Lynch-Fair-Value 0.55
Price-to-Graham-Number 2.20
Earnings Yield (Joel Greenblatt) % 13.10
Forward Rate of Return (Yacktman) % 25.65

More Statistics

Revenue (TTM) (Mil) $ 13,452.9
EPS (TTM) $ 21.6
Beta 1.85
Volatility % 41.83
52-Week Range $ 216.12 - 388.67
Shares Outstanding (Mil) 196.71

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y